Lack of the Nlrp3 Inflammasome Improves Mice Recovery Following Traumatic Brain Injury.

Abstract

Treatment for traumatic brain injury (TBI) remains elusive despite compelling evidence from animal models for a variety of therapeutic targets. The activation of the NLRP3 (Nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3) inflammasome has been proposed as key point in the brain damage associated with TBI. NLRP3 was tested as potential target for reducing neuronal loss and promoting functional recovery in a mouse model of TBI. Male NLRP3-/- (n = 20) and wild type (n = 27) mice were used. A closed TBI model was performed and inflammatory and apoptotic markers were evaluated. A group of WT mice also received BAY 11-7082, a NLRP3 inhibitor, to further evaluate the role of this pathway. At 24 h following TBI NLRP3-/- animals demonstrated a preserved cognitive function as compared to WT mice, additionally brain damage was less severe and the inflammatory mediators were reduced in brain lysates. The administration of BAY 11-7082 in WT animals subjected to TBI produced overlapping results. At day 7 histology revealed a more conserved brain structure with reduced damage in TBI NLRP3-/- animals compared to WT. Our data indicate that the NLRP3 pathway might be exploited as molecular target for the short-term sequelae of TBI.

• Authors: Natasha Irrera, Gabriele Pizzino, Margherita Calò, Giovanni Pallio, Federica Mannino, Fausto Famà, Vincenzo Arcoraci, Vincenzo Fodale, Antonio David, Cosentino Francesca, Letteria Minutoli, Emanuela Mazzon, Placido Bramanti, Francesco Squadrito, Domenica Altavilla, Alessandra Bitto
• Journal: Frontiers in pharmacology (Front Pharmacol) Vol. 8 Pg. 459 ( 2017) ISSN: 1663-9812 [Print] Switzerland
• PMID: 28769794 (Publication Type: Journal Article)